Table 1 Distribution of patient and tumor characteristics by randomization arm.

		Total (n = 3 690)	Randomization arm
			FEC-D (n = 1 861)	FEC-DG (n = 1 829)
Age (years)	median	53.0	54.0	53.0
	range	21–86	21–86	22–85
Menopausal status	premenopausal	1 542 (41.8 %)	765 (41.1 %)	777 (42.5 %)
	postmenopausal	2 148 (58.2 %)	1 096 (58.9 %)	1 052 (57.5 %)
Tumor size	pT1	1 538 (41.7 %)	765 (41.1 %)	773 (42.3 %)
	pT2	1 901 (51.5 %)	964 (51.8 %)	937 (51.2 %)
	pT3	194 (5.3 %)	105 (5.6 %)	89 (4.9 %)
	pT4	52 (1.4 %)	26 (1.4 %)	26 (1.4 %)
	unknown	5 (0.1 %)	1 (0.1 %)	4 (0.2 %)
Nodal stage	pN0	1 257 (34.1 %)	623 (33.5 %)	634 (34.7 %)
	pN1	1 684 (45.6 %)	868 (46.6 %)	816 (44.6 %)
	pN2	507 (13.7 %)	249 (13.4 %)	258 (14.1 %)
	pN3	232 (6.3 %)	118 (6.3 %)	114 (6.2 %)
	unknown	10 (0.3 %)	3 (0.2 %)	7 (0.4 %)
Histological grading	G1	176 (4.8 %)	79 (4.2 %)	97 (5.3 %)
	G2	1 754 (47.5 %)	887 (47.7 %)	867 (47.4 %)
	G3	1 756 (47.6 %)	893 (48.0 %)	863 (47.2 %)
	unknown	4 (0.1 %)	2 (0.1 %)	2 (0.1 %)
Histological type	invasive ductal	3 027 (82.0 %)	1 527 (82.1 %)	1 500 (82.0 %)
	invasive lobular	408 (11.1 %)	207 (11.1 %)	201 (11.0 %)
	other	251 (6.8 %)	125 (6.7 %)	126 (6.9 %)
	unknown	4 (0.1 %)	2 (0.1 %)	2 (0.1 %)
Estrogen receptor status	negative	1 243 (33.7 %)	605 (32.5 %)	638 (34.9 %)
	positive	2 444 (66.2 %)	1 254 (67.4 %)	1 190 (65.1 %)
	unknown	3 (0.1 %)	2 (0.1 %)	1 (0.1 %)
Progesterone receptor status	negative	1 510 (40.9 %)	760 (40.8 %)	750 (41.0 %)
	positive	2 174 (58.9 %)	1 096 (58.9 %)	1 078 (58.9 %)
	unknown	6 (0.2 %)	5 (0.3 %)	1 (0.1 %)
Her2 status	negative	2 748 (74.5 %)	1 392 (74.8 %)	1 356 (74.1 %)
	positive	877 (23.8 %)	434 (23.3 %)	443 (24.2 %)
	unknown	65 (1.8 %)	35 (1.9 %)	30 (1.6 %)
Type of surgery	breast conserving	2 606 (70.6 %)	1 308 (70.3 %)	1 298 (71.0 %)
	mastectomy	1 083 (29.3 %)	553 (29.7 %)	530 (29.0 %)
	unknown	1 (0.0 %)	0 (0.0 %)	1 (0.1 %)
Radiotherapy	no	530 (14.4 %)	257 (13.8 %)	273 (14.9 %)
	yes	3 148 (85.3 %)	1 597 (85.8 %)	1 551 (84.8 %)
	unknown	12 (0.3 %)	7 (0.4 %)	5 (0.3 %)